ArticleJournal of cancer research and clinical oncology2011
OLFM4 is associated with lymph node metastasis and poor prognosis in patients with gastric cancer.
Article in Journal of cancer research and clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 46 citations in OpenAlex.
- Single-Cell Transcriptomic Analysis Identifies an OLFM4-Associated Gastric Cancer Cell State with Palmitoylation-Related Signatures and Altered Metabolic Activities.Biomolecules · 2026Article
- Article
- Olfactomedin 4 in cancer development and progression.Biochimica et biophysica acta. Reviews on cancer · 2025Review
- Olfactomedin 4 promotes gastric cancer cell G2/M progression and serves as a therapeutic target in gastric adenocarcinoma.Carcinogenesis · 2025Article
- PLASMA: Partial LeAst Squares for Multiomics Analysis.Cancers · 2025Article
- Review
- Epstein-Barr virus infection upregulates extracellular OLFM4 to activate YAP signaling during gastric cancer progression.Nature communications · 2024Article
- Olfactomedin 4 produces dysplasia but suppresses metastasis of colon cancer.Cancer gene therapy · 2023Article
- Comprehensive Analysis of Gene Expression Profiling to Explore Predictive Markers for Eradication Therapy Efficacy againstCancers · 2023Article
- Olfactomedin 4 associates with expression of differentiation markers but not with properties of cancer stemness, EMT nor metastatic spread in colorectal cancer.The journal of pathology. Clinical research · 2023Article
- OLFM4 depletion sensitizes gallbladder cancer cells to cisplatin through the ARL6IP1/caspase-3 axis.Translational oncology · 2022Article
- High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer.PloS one · 2020Article
- Olfactomedin domain-containing proteins: evolution, functional divergence, expression patterns and damaging SNPs.Molecular genetics and genomics : MGG · 2019Article
- Olfactomedin 4 (OLFM4) expression is associated with nodal metastases in esophageal adenocarcinoma.PloS one · 2019Article
- OLFM4, LY6D and S100A7 as potent markers for distant metastasis in estrogen receptor-positive breast carcinoma.Cancer science · 2018Article
- Olfactomedin-4 in digestive diseases: A mini-review.World journal of gastroenterology · 2018Review
- Identification of differentially-expressed of Olfactomedin-related proteins 4 and COL11A1 in Iranian patients with intestinal gastric cancer.Gastroenterology and hepatology from bed to bench · 2017Article
- High Hepsin expression predicts poor prognosis in Gastric Cancer.Scientific reports · 2016Article
- Loss of OLFM4 promotes tumor migration through inducing interleukin-8 expression and predicts lymph node metastasis in early gastric cancer.Oncogenesis · 2016Article
- Estrogen receptor-mediated miR-486-5p regulation of OLFM4 expression in ovarian cancer.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe present study investigated the clinical significance of the relationship between olfactomedin 4 (OLFM4) expression and the clinicopathological features of patients with gastric cancer.
methodsTumor tissue and adjacent normal tissue, lymph nodes, and peritoneal metastases were analyzed by the Affymetrix GeneChip(®) HG-U133A2.0 array. The expression of OLFM4 was detected by real-time quantitative RT-PCR in gastric tumor tissue and adjacent normal tissue. OLFM4 expression was analyzed by immunohistochemistry in 436 clinicopathologically characterized gastric cancer cases and in corresponding distant metastases from 61 patients.
resultsA total of 434 genes and 169 expressed sequence tags were upregulated, including OLFM4. The expression of OLFM4 mRNA or protein differed significantly among gastric tumor tissue, matched normal gastric mucosa, and lymph node metastases. Further multivariate analysis suggested that lymph node metastases and distant metastases, TNM stage, and expression of OLFM4 were independent prognostic indicators for gastric cancer.
conclusionGene expression profiles were useful for simultaneously analyzing the expression levels of thousands of genes. Reduced expression of OLFM4 in gastric cancer is associated significantly with lymph node and distant metastases and with poor prognosis. OLFM4 may prove to be an important molecular marker for predicting the carcinogenesis, development, progression, and metastasis of gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.